Drug Trial Radar · NCT01733459
Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)
Last checked: Nov 19, 2026Latest source record: Jul 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Mar 2013
Primary completion
Apr 2018
Study completion Jun 2018
Sponsor
- Lead sponsor
- Dexa Medica GroupIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-arm, randomized, double-blind, double-dummy, and controlled clinical study, with 6 months of treatment to evaluate the clinical and metabolic efficacy of DLBS3233 in improving reproductive parameters and to evaluate the safety of DLBS3233 in women with polycystic ovary syndrome compared with metformin, as an active control.
Conditions
- Polycystic Ovary Syndrome (PCOS)
Interventions
DLBS3233Drug
1 DLBS3233 capsule 100 mg once daily for 6 months
Metformin XRDrug
1 Metformin XR caplet 750 mg twice daily for 6 months
Placebo caplet of Metformin XRDrug
1 placebo caplet of Metformin XR twice daily for 6 months
Placebo capsule of DLBS3233Drug
1 placebo capsule of DLBS3233 once daily for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- HOMA-IR reductionTime frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, dr. Cipto Mangunkusumo Hospital
Jakarta, Indonesia
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Padjadjaran, Hasan Sadikin Hospital
Bandung, West Java, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.